Ultragenyx Pharmaceutical Inc (RARE) USD0.001

Sell:$38.06Buy:$38.10$0.35 (0.93%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$38.06
Buy:$38.10
Change:$0.35 (0.93%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$38.06
Buy:$38.10
Change:$0.35 (0.93%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Key people

Emil D. Kakkis
President, Chief Executive Officer, Director
Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Eric Crombez
Executive Vice President, Chief Medical Officer
Erik Harris
Executive Vice President, Chief Commercial Officer
Thomas Kassberg
Chief Business Officer, Executive Vice President
Karah Parschauer
Executive Vice President, Chief Legal Officer, Corporate Affairs
John R. Pinion
Chief Quality Officer, Executive Vice President - Translational Sciences
Daniel G. Welch
Independent Chairman of the Board
Deborah L. Dunsire
Independent Director
Matthew K. Fust
Independent Director
Michael A. Narachi
Independent Director
Amrit Ray
Independent Director
Click to see more

Key facts

  • EPIC
    RARE
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US90400D1081
  • Market cap
    $3.50bn
  • Employees
    1,294
  • Shares in issue
    93.97m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.